Related references
Note: Only part of the references are listed.Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype
Brenda Deyarmin et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Variation in the Utilization of Reconstruction Following Mastectomy in Elderly Women
Haejin In et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Trends in Radiotherapy After Breast-Conserving Surgery in Elderly Patients with Early-Stage Breast Cancer
Carrie Luu et al.
ANNALS OF SURGICAL ONCOLOGY (2013)
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry
E. C. Inwald et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response
E. H. Lips et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
G. Allevi et al.
BRITISH JOURNAL OF CANCER (2013)
Long-term outcome of neoadjuvant systemic therapy for locally advanced breast cancer in routine clinical practice
Domenico Angelucci et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Clara Natoli et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Management of operable breast cancer in older women
Ian S. Fentiman
JOURNAL OF THE ROYAL SOCIETY OF MEDICINE (2013)
Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer
Manfred Kaufmann et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II)
Milvia Zambetti et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically distinct subgroups
Mohammed A. Aleskandarany et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor-Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype-ACOSOG Z1031
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Relevance of Breast Cancer Subtypes in the Outcome of Neoadjuvant Chemotherapy
M. E. Straver et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Effect of neoadjuvant anthracycline-taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study
Jens Huober et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer
Marie Klintman et al.
MODERN PATHOLOGY (2010)
Ki67 in breast cancer: prognostic and predictive potential
Rinat Yerushalmi et al.
LANCET ONCOLOGY (2010)
Molecular Subtypes and Tumor Response to Neoadjuvant Chemotherapy in Patients with Locally Advanced Breast Cancer
Seung Il Kim et al.
ONCOLOGY (2010)
Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy
Marco Colleoni et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
A. Barnadas et al.
BRITISH JOURNAL OF CANCER (2009)
Meta-analysis of pre-operative aromatase inhibitor versus tamoxifen in postmenopausal woman with hormone receptor-positive breast cancer
Jae Hong Seo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
Maggie C. U. Cheang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Proliferation markers and survival in early breast cancer: A systematic review and meta-analysis of 85 studies in 32,825 patients
R. Stuart-Harris et al.
BREAST (2008)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics
Matthew J. Ellis et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Birgitte B. Rasmussen et al.
LANCET ONCOLOGY (2008)
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
Norman Williams
LANCET ONCOLOGY (2008)
American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer
Lyndsay Harris et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
[Anonymous]
JOURNAL OF ONCOLOGY PRACTICE (2007)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients
E. de Azambuja et al.
BRITISH JOURNAL OF CANCER (2007)
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. C. Coombes et al.
LANCET (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
Mitch Dowsett et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients
Alberto Bottini et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer - The Pre-Operative Arimidex Compared to Tamoxilen (PROAC7) trial
L Cataliotti et al.
CANCER (2006)
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Proliferation marker Ki-67 in early breast cancer
A Urruticoechea et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial
IE Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Breast cancer treatment in older women: Does getting what you want improve your long-term body image and mental health?
ML Figueiredo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Radiotherapy after breast-conserving surgery in small breast carcinoma: Long-term results of a randomized trial
U Veronesi et al.
ANNALS OF ONCOLOGY (2001)
Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study
W Eiermann et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
